Head to Head Review: Tilray Brands (NASDAQ:TLRY) & Oramed Pharmaceuticals (NASDAQ:ORMP)

Oramed Pharmaceuticals (NASDAQ:ORMP) and Tilray Brands (NASDAQ:TLRY) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and valuation.

Risk and Volatility

Oramed Pharmaceuticals has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, Tilray Brands has a beta of 1.77, meaning that its share price is 77% more volatile than the S&P 500.

Profitability

This table compares Oramed Pharmaceuticals and Tilray Brands’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oramed Pharmaceuticals	N/A	-5.57%	-5.22%
Tilray Brands	-251.69%	-6.05%	-4.57%

Insider and Institutional Ownership

12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.4% of Tilray Brands shares are owned by institutional investors. 17.8% of Oramed Pharmaceuticals shares are owned by insiders. Comparatively, 0.8% of Tilray Brands shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings for Oramed Pharmaceuticals and Tilray Brands, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oramed Pharmaceuticals	0	1	0	0	2.00
Tilray Brands	1	4	2	0	2.14

Tilray Brands has a consensus target price of $20.00, indicating a potential upside of 117.86%. Given Tilray Brands’ stronger consensus rating and higher possible upside, analysts plainly believe Tilray Brands is more favorable than Oramed Pharmaceuticals.

Earnings and Valuation

This table compares Oramed Pharmaceuticals and Tilray Brands”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oramed Pharmaceuticals	$1.34 million	101.88	-$19.06 million	$1.26	2.72
Tilray Brands	$821.31 million	1.26	-$2.19 billion	($22.70)	-0.40

Oramed Pharmaceuticals has higher earnings, but lower revenue than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Oramed Pharmaceuticals beats Tilray Brands on 8 of the 14 factors compared between the two stocks.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

About Tilray Brands

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.